USPTO serial 76307432
INVOLIN
Reviewed by CopyMark Law Group
Reg. 2954070Status 710
- Filing date
- Status date
- Registration date
- May 24, 2005
- Examiner
- JOHNSON, AISHA CLARKE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 710 means the registration was cancelled because a required Section 8 declaration of continued use was not filed within the deadline (including any grace period). The federal registration is no longer active. Evaluate filing a new application if you still use the mark, or petition if cancellation was erroneous. Consult counsel on remaining common-law rights.
Need help with INVOLIN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
75724, PARIS Cedex 15, FR
75724, PARIS Cedex 15, FR
75724, PARIS Cedex 15, FR
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Barry L. Kelmachter
BARRY L KELMACHTER BACHMAN & LAPOINTE PC900 CHAPEL ST STE 1201NEW HAVEN, CT 06510-2809UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | chemical, biochemical, biotechnological products intended for industry, the sciences, agriculture, and horticulture, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases for scientific research use; cells engineered by meganuclease recombination systems for scientific, laboratory or medical research; chemical, biochemical, biotechnological and bacteriological products intended for research laboratories and control laboratories, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases for scientific research; deoxyribonucleic acid reagents for scientific research use, namely for the transport of biological molecules; microorganism cultures and preprations for use in the manufacture of human and veterinary pharmaceuticals, namely microorganisms engineered by meganuclease recombination systems, microorganisms producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; microorganisms used for producing therapeutic compounds or vaccines; microorganism cultures and preparations for medical research use, namely microorganisms engineered by meganuclease recombination systems, microorganisms producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; bacteriological preparations for medical research use, namely bacteriological preparations engineered by meganuclease recombination systems, bacteriological preparations producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; bacteriological preparations for use in the manufacture of human and veterinary pharmaceuticals, namely bacteriological preparations engineered by meganuclease recombination systems, bacteriological preparations producing polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of reagents and endocnuclease | SECTION 8 - CANCELLED | — |
| 005 | Pharmaceutical, veterinary and health-care products, namely polypeptides for in vivo and in vitro genetic engineering for clinical use; natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonuclease for clinical use; cells engineered by meganuclease recombination systems for clinical use; microorganism cultures and preparations for clinical medical use, namely microorganisms engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases, and nucleic acid vectors; microorganism cultures and preparations for use as human and veterinary pharmaceuticals, namely microorganisms engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and microorganisms used for producing therapeutic compounds or vaccines; bacteriological preparations for clinical medical use, namely bacteriologic preparations engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases and nucleic acid vectors; bacteriological preparations for use as human and veterinary pharmaceuticals, namely bacteriological preparations engineered by meganuclease recombination systems, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, and ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases; drugs for clinical medical use, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors; drugs for use as human and veterinary pharmaceuticals, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, and molecular scissors; biological preparations for clinical medical use, namely polypeptides for in vivo in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and cells engineered by meganuclease recombination systems; drugs for use as human and veterinary pharmaceuticals, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and cells engineered by meganuclease recombination systems; chemical biochemical preparations for clinical medical use, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonuclease, and cells engineered by meganuclease recombination systems; chemical and biochemical preparations for use as human and veterinary pharmaceuticals, namely polypeptides for in vivo and in vitro genetic engineering, natural and engineered meganucleases and endonucleases, nucleic acid vectors, molecular scissors, ready to use genomic recombination systems primarily composed of DNA reagents and endonucleases, and cells engineered by meganuclease recombination systems; chemopharmaceutical products | SECTION 8 - CANCELLED | — |
| 042 | Scientific and industrial research; research in genetic, medical, pharmaceutical, veterinary, botanic and microbiological fields; research in chemistry, biology, biochemistry, molecular biology, and bacteriology; research and development for others of techniques of biochemical analysis, biological analysis, and molecular biology techniques; scientific transgenesis research of deoxyribonucleic acid for the preparation or conveying of biological molecules; scientific analysis namely in genetic, medical, pharmaceutical, veterinary, botanic and microbiological fields; research and development for others of new molecules intended for industry; laboratory research in the fields of biotechnology, human and veterinary medicine, genetic engineering, protein design, drug design, genetic therapy, molecular biology, and agriculture; medical services; studies of technical projects in the field of biotechnology, human and veterinary medicine, genetic engineering, protein design, drug design, genetic therapy, molecular biology, and agriculture; testing, analysis and evaluation of engineering works for others; licensing of patents and intellectual property; computer programming for others, development for others of multimedia software programs | SECTION 8 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CELLECTIS S.A.
- Other trademarks owned by CELLECTIS S.A.
- Other trademarks owned by CELLECTIS S.A.
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named INVOLIN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Dec 30, 2011 | C8.. | CANCELLED SEC. 8 (6-YR) | — |
| May 24, 2005 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 25, 2005 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Mar 25, 2005 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Sep 9, 2004 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Jun 2, 2004 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| May 4, 2004 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Apr 14, 2004 | NPUB | NOTICE OF PUBLICATION | — |
| Feb 10, 2004 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Oct 18, 2003 | CFIT | CASE FILE IN TICRS | — |
| Oct 8, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 8, 2003 | FAXX | FAX RECEIVED | — |
| Oct 3, 2003 | CNCF | CONTINUATION OF FINAL REFUSAL MAILED | — |
| Sep 16, 2003 | ZZZY | PREVIOUS ACTION COUNT WITHDRAWN | — |
| Sep 15, 2003 | ZZZX | PREVIOUS ALLOWANCE COUNT WITHDRAWN | — |
| May 20, 2003 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| May 12, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| May 7, 2003 | CNCF | CONTINUATION OF FINAL REFUSAL MAILED | — |
| Mar 10, 2003 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Mar 10, 2003 | PAPER RECEIVED | — | |
| Nov 15, 2002 | CNFR | FINAL REFUSAL MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 14, 2002 | 1.BD | Sec. 1(B) CLAIM DELETED | — |
| Oct 8, 2002 | DOCK | ASSIGNED TO EXAMINER | — |
| May 6, 2002 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 9, 2001 | CNRT | NON-FINAL ACTION MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 2, 2001 | DOCK | ASSIGNED TO EXAMINER | — |